# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price targ...
In addition, Cytek expects to report a net loss in the single digit millions for the full year 2024 (prior view: report positiv...
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $...
Today Cytek Biosciences, Inc. (NASDAQ:CTKB) announced that it has developed a revolutionary tool to automate panel design. The ...
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price targ...